Epstein Conspiracies, US Drug Manufacturing, Student Loan Overhaul

Summary

Up First from NPR – July 19, 2025 Edition

NPR’s "Up First" delivers the three biggest stories of the day with in-depth reporting and analysis. In this episode, hosts Scott Simon and Adrian Ma delve into the persistent conspiracy theories surrounding Jeffrey Epstein, the U.S. pharmaceutical industry's dependence on foreign manufacturing, and significant changes to the federal student loan system.

---

1. Epstein Conspiracy Theories and Political Repercussions

Timestamp: 00:02 – 05:57

The episode opens with Scott Simon and Adrian Ma addressing the enduring conspiracy theories surrounding Jeffrey Epstein, who died in custody in 2019 while awaiting trial on sex trafficking charges.

• Scott Simon introduces the topic: “He's been dead nearly six years. But conspiracy theories about Jeffrey Epstein are stronger than ever. Will those who believe them be satisfied by any release of information?” (00:02 – 00:08)

• Adrian Ma highlights President Donald Trump's recent actions: “President Trump is pressuring drug manufacturers to start making meds in the US or face tariffs and major changes to the federal student loan system.” (00:18 – 00:32)

• Lisa Hagan, NPR's correspondent on conspiracy theories, provides insight into the public's reaction to potential releases of Epstein's records: “If you're a media figure or a politician who's risen to prominence supporting Trump... you're probably fairly desperate at this moment for any evidence to hold up and say, see, Trump is keeping his promises to be transparent.” (03:05 – 03:52)

• Lisa Hagan further discusses various public segments, including conspiracy theorists: “If you're one of the many people who believe in qanine style demonic pedophile cabals running the world... the satisfaction you've been waiting on, like, for years is arresting and executing that cabal, not a grand jury report.” (03:52 – 05:54)

The segment underscores the complexity of public perception regarding Epstein, especially among different political and conspiracy theory communities, and emphasizes the real human impact, mentioning the suicide of an Epstein abuse survivor.

---

2. U.S. Pharmaceutical Manufacturing and Trump’s Tariff Strategy

Timestamp: 06:03 – 10:03

The discussion shifts to the U.S. pharmaceutical industry's heavy reliance on foreign manufacturing and President Trump’s administration's efforts to bring drug production back to American soil through proposed tariffs.

• Adrian Ma introduces the topic: “President Trump is pushing pharmaceutical companies to move manufacturing back to the US this week he increased that pressure by saying he would impose tariffs on drug makers soon as August 1.” (06:03 – 06:15)

• Sidney Lupkin, NPR's pharmaceuticals correspondent, provides statistics: “Most of them [medicines] are actually. Many of the key ingredients are made in China and most generics are made in India.” (06:35 – 06:46)

• Sidney Lupkin explains the vulnerability exposed by the COVID-19 pandemic: “The United States was really made aware of how vulnerable its drug supply was when Covid hit suddenly Chinese drug factories shut down. India restricted drug exports.” (06:46 – 07:18)

• Sidney Lupkin discusses the technical and logistical challenges of moving manufacturing domestically: “It's a big lift to move factories for even just one drug... You have to establish all your procedures for that site.” (07:21 – 08:25)

• Sidney Lupkin outlines the potential consequences of imposing tariffs: “Drugs could get more expensive for consumers or tariffs could result in access issues if companies stop selling foreign made products here, especially generics.” (09:34 – 09:54)

The segment concludes by highlighting the mixed reactions within the pharmaceutical industry, with some companies like Eli Lilly expanding domestic manufacturing despite the long timelines and economic challenges posed by tariffs.

---

3. Overhaul of the Federal Student Loan System

Timestamp: 10:03 – 16:02

Adrian Ma and Scott Simon turn their attention to the recent comprehensive changes in the federal student loan system enacted by President Trump’s administration, emphasizing how these changes will affect both new and current borrowers.

• Adrian Ma introduces the topic: “Among the many changes in the big spending package President Trump recently signed into law, there's also a complete overhaul of the federal student loan system.” (10:03 – 10:21)

• Cory Turner, NPR’s education correspondent, explains the new limits for borrowers: “For anyone taking out loans after July 1, 2026... there will be new stricter limits also for parents and caregivers who take out what are called parent plus loans to help their kids pay for college.” (10:27 – 11:26)

• Cory Turner outlines the new repayment options under the overhaul: “This new Republican law is shifting the system from at least seven loan repayment plans down to two... one is a standard plan based on debt and monthly payments, and the other is a repayment assistance plan (RAP) based on income.” (11:26 – 13:08)

  • Roxanne Garza, director of Higher Ed Policy at the Ed Trust, is quoted: “If your monthly payment does not reduce your principal by at least $50, the federal government will essentially top you off to reduce that principal by $50.” (12:28 – 12:34)

• Cory Turner discusses the limited scope of loan forgiveness under the new system: “Borrowers who have typical levels of debt and typical incomes for their degree level are almost always going to pay off well before they hit that 30-year mark.” (13:19 – 13:33)

• Adrian Ma raises concerns about the administration’s efforts to restructure the Education Department: “The Trump administration is exploring moving student loans either to the Small Business Administration or to Treasury... staffing levels have been cut roughly in half.” (15:03 – 15:58)

This segment highlights significant policy shifts that reduce the flexibility of repayment plans and potentially increase the financial burden on borrowers, while also addressing administrative challenges amid proposed Department of Education cuts.

---

Conclusion

In this episode of "Up First," NPR provides a comprehensive overview of pressing national issues: the enduring conspiracy theories surrounding Jeffrey Epstein and their political implications, the strategic moves by the Trump administration to bolster domestic pharmaceutical manufacturing amid global dependencies, and the sweeping changes to the federal student loan system that could reshape the financial landscape for millions of Americans. Through expert interviews and detailed analysis, the episode offers listeners a nuanced understanding of these complex topics.

Transcript

[Scott Simon]

He's been dead nearly six years.

[Adrian Ma]

But conspiracy theories about Jeffrey Epstein are stronger than ever.

[Scott Simon]

Will those who believe them be satisfied by any release of information? I'm Scott Simon.

[Adrian Ma]

And I'm Adrian Ma. And this is up first from NPR News.

[Scott Simon]

That bottle of pain reliever on our editor's desk. Well, those pills were made in India. Broadly speaking, we are very dependent on foreign suppliers.

[Adrian Ma]

Is that about to change? President Trump is pressuring drug manufacturers to start making meds in the US or.

[Scott Simon]

Face tariffs and major changes to the federal student loan system. Some repayment plans are getting phased out. There are limits for some new borrowers.

[Adrian Ma]

We have details, so stay with us. We'll have the news you need to start your weekend.

[Judy Abrams]

Support for this podcast and the following message come from Fisher Investments SVP Judy Abrams shares how their fiduciary duty comes to life while helping clients plan for retirement.

[Lisa Hagan]

Fisher Investments is a fiduciary. And I think one of the very important roles we have here as a fiduciary is to help expand people's thinking about what this money is needed to do for them.

[Judy Abrams]

Learn [e-mail] Investing in securities involves the risk of loss. This message comes from NPR's sponsor, Odoo Business Management Software. Some say Odoo is like fertilizer because it promotes growth. Others say it's a magic beanstalk scaling with efficiency. Odoo, exactly what a business needs. Sign up [e-mail] this message comes from Dell Technologies.

[Cory Turner]

The new Dell AI PC with Intel Core Ultra helps fast forward through busywork, leaving more time for you. Time Get a new Dell AI PC starting at $699.99 at Dell.com AI PC@.

[Adrian Ma]

President Donald Trump's direction, the Justice Department has asked the federal judge to unseal more records related to Jeffrey Epstein, who died in custody while awaiting trial on sex trafficking charges in 2019, as follows.

[Scott Simon]

New reporting from the Wall Street Journal. That's renewed scrutiny on the long term friendship between Trump and Epstein.

[Adrian Ma]

Trump is dismissing the Journal's reporting as fake and is now suing it and its owners, including Rupert Murdoch, for at least $10 billion.

[Scott Simon]

The Epstein case has long been a focus of conspiracy theories, which NPR's Lisa Hagan has covered, and she joins us now. Lisa, thanks for being with us.

[Lisa Hagan]

Hey there.

[Scott Simon]

The president says he wants grand jury evidence related to Epstein released. Setting aside whether a judge will agree to that or not, how much would that satisfy the people's desire for information.

[Lisa Hagan]

In this case, I think the Answer to that depends on what gets released, obviously, but it also really depends on who you are. So how about we go through a few different categories of people, like folks with ties to Trump, people with stronger ties to conspiracy communities, and maybe everybody else.

[Scott Simon]

Let's begin with people who are tied to Donald Trump. Will they be satisfied?

[Lisa Hagan]

If you're a media figure or a politician who's risen to prominence supporting Trump and that's your audience, you, you're probably fairly desperate at this moment for any evidence to hold up and say, see, Trump is keeping his promises to be transparent. As long as it's not. Forget about Epstein already. You're likely to frame what the administration offers in a flattering light, including reasonable sounding ways to kick the can down the road. Not all of your audience will buy that. But by now we have more than a decade of Trump style politics that shows us plenty of people will continue supporting this president. So people who watch and trust pro Trump media are waiting on cues that it's okay to ignore all the nothing burger hubbub right now and that it's all coming from people who are out to get Trump.

[Scott Simon]

What about people who've bought more seriously into conspiracy theories about Jeffrey Epstein?

[Lisa Hagan]

So we've got people whose livelihoods and communities have come together by searching out like cryptic details or Internet message boards to interpret future government policy. Let's be clear, there's overlap between these two first categories, which has made the last few weeks pretty uncomfortable for some people. What I've seen in some of the conspiracy theorists spaces is begrudging coverage of some of these Epstein headlines like, okay, we have to talk about this, but here are a bunch of other things we'd rather be talking about. If you're one of the many people who believe in qanine style demonic pedophile cabals running the world, the satisfaction you've been waiting on, like, for years is arresting and executing that cabal, not a grand jury report. But paradoxically, the narratives that have helped them wait this long for justice are also likely to continue to hold. So you're also looking for signs like a pregnant pause or a look or a phrase that confirms, okay, we just have to trust Trump knows what he's doing.

[Scott Simon]

Where does this leave people who aren't in any of these groups and everybody else, right?

[Lisa Hagan]

Like people who don't like Trump or people who don't mind him either way, or like anyone else who's followed the Epstein story. The details of the story are awful, but I look around and I see plenty of people deriving a kind of enjoyment from spinning theories founded or unfounded. And some people are currently remembering or learning for the first time that, oh yeah, Donald Trump did have a for real friendship with Jeffrey EPSTEIN in the 1980s and 90s. And you know what, it does seem weird that the president just told everyone to forget about it. There have always been details about Epstein that raise doubts. For people having doubts doesn't make you a conspiracy theorist. Tying those doubts to rigid narratives about good and evil and rejecting reasonable evidence that contradicts what you want to believe, that's conspiracism. And I think in this hurricane of politics and speculation, we also have to remember that Epstein hurt real people. One of the survivors of his abuse died by suicide just this April.

[Scott Simon]

NPR's Lisa Hagan, thanks so much.

[Lisa Hagan]

Thank you.

[Adrian Ma]

President Trump is pushing pharmaceutical companies to move manufacturing back to the US this.

[Scott Simon]

Week he increased that pressure by saying he would impose tariffs on drug makers soon as August 1.

[Adrian Ma]

The tariffs would start low to give companies a year or so to build factories here and then rapidly increase.

[Scott Simon]

NPR pharmaceuticals correspondent Sidney Lupkin joins us now. Sidney, thanks for being with us.

[Sidney Lupkin]

Thanks for having me.

[Scott Simon]

Help us get hold of the problem. How many of our medicines are actually made outside the US A lot of them.

[Sidney Lupkin]

Most of them, actually. Many of the key ingredients are made in China and most generics are made in India. That's according to economist Jeffrey Joyce, the director of health policy at the USC Schaeffer Center.

[Scott Simon]

Some final formulation may be done in the US but broadly speaking, we are very dependent on foreign suppliers. It's less intensive on for branded or on patent drugs. But still we are very dependent as well on overseas production.

[Sidney Lupkin]

The United States was really made aware of how vulnerable its drug supply was when Covid hit suddenly Chinese drug factories shut down. India restricted drug exports. So having more drugs produced in the U.S. especially essential medicines, is broadly considered a good policy.

[Scott Simon]

How is it that manufacturing moved outside the US Anyway?

[Sidney Lupkin]

Yeah, there are tax incentives for manufacturing overseas. So by manufacturing name brand drugs in Ireland, for example, companies can report profits there and pay a very low corporate tax rate for generics because they compete mostly on price. Companies manufacture in places with lower wages, like India and China. The tariffs are an effort to shift production back to the US Soil by basically punishing companies for foreign manufacturing.

[Scott Simon]

Will that work?

[Sidney Lupkin]

It's complicated. Joyce says he thinks it would take a lot more incentives to convince companies to do it, tax breaks, subsidies, things like that. I also spoke to Chris Middendorf, who spent years at the Food and Drug Administration inspecting factories in India and China. And he's now at the law firm Hogan Levels. And he says it's a big lift to move factories for even just one drug.

[Lisa Hagan]

It's not just about like putting equipment.

[Scott Simon]

In and starting to manufacture.

[Lisa Hagan]

It's like you have to qualify the.

[Scott Simon]

Building, you have to qualify all your equipment in there. Like you have to establish all your procedures for that site.

[Lisa Hagan]

It's a lot more than just building a building.

[Sidney Lupkin]

Companies need to prove they can correctly make the drug at a new factory because if they can't, the consequences for patients could be dire.

[Scott Simon]

Yeah, of course the pharmaceuticals could be harmful.

[Sidney Lupkin]

Yeah. All that said, some companies have already announced they're expanding in the U.S. eli Lilly is beefing up its domestic manufacturing, including at sites in Indiana and North Carolina. And in February it said that it would be spending billions more dollars to add four new factories. But Lilly says it could take as long as five years for these factories to come online. So that's the realistic timeline.

[Scott Simon]

Sidney, could companies just basically ignore the tariffs or absorb them and leave manufacturing overseas?

[Sidney Lupkin]

Yes, absolutely. That's an option. The pharmaceutical tariff doesn't exist in a vacuum. There are a bunch of other tariffs too. If a company decides to a facility in the US it might still get hit with tariffs, importing equipment. And for generic manufacturers whose profits are razor thin, a tariff might not be much of an incentive to move production. They might pass along the tariff cost to consumers or pull out of the market altogether.

[Scott Simon]

What would the consequences of that be for patients?

[Sidney Lupkin]

Both Joyce and Middendorf expect drugs would get more expensive for consumers or tariffs could result in access issues if companies stop selling foreign made products here, especially generics. The big questions now are will the drug tariffs really be the 200% President Trump is threatening or something lower? And will they stick?

[Scott Simon]

NPR pharmaceuticals correspondent Sidney Lupkin, thanks so much.

[Sidney Lupkin]

You bet.

[Scott Simon]

If you have student loans or hope to take out student loans in the next few years, you may want to listen extra closely to this next conversation.

[Adrian Ma]

That's because among the many changes in the big spending package President Trump recently signed into law, there's also a complete overhaul of the federal student loan system.

[Scott Simon]

Places new limits on loans for many borrowers, and it ends most current repayment plans.

[Adrian Ma]

For more on what these changes mean, we're joined by NPR education correspondent Cory Turner. Thanks for being here, Cory.

[Cory Turner]

Thank you, Adrian.

[Adrian Ma]

Let's start off talking about new borrowers, folks who may be taking out their student loans next year. What do they need to know?

[Cory Turner]

Yes. So for anyone taking out loans after July 1, 2026. They need to know that this law includes a handful of new limits on how much money certain borrowers can actually take out from the government. The good news for undergrads is those limits aren't changing. For graduate students though, it's a different story. There will be new stricter limits also for parents and caregivers who take out what are called parent plus loans to help their kids pay for college. New strict limits as well. And I will say one fear I heard from borrow advocates is that these new limits could drive some lower income borrowers into the private loan market where there really aren't as many consumer protections.

[Adrian Ma]

So for these newer borrowers, what kind of options will they have when it comes to repaying their loans?

[Cory Turner]

Sure. Well, this new Republican law is shifting the system from at least seven loan repayment plans down to two. And again, this is for new loans starting next summer. There is an updated version of a standard plan which is your repayment window is based on how much debt you have have and your monthly payments are all the same like a home mortgage. The other option is a little more complicated. It's something Republicans are calling their repayment assistance plan or rap, and it bases monthly payments on a borrower's income. It waives interest that a borrower's monthly payment does not cover. So loans aren't going to be ballooning over time. It also comes with a new idea, Adrian. It's a matching principle payment, basically for folks whose monthly payments barely make a dent in their principal balance. Here's one explanation from Roxanne Garza. She's director of Higher Ed policy at the liberal leaning Ed Trust.

[Lisa Hagan]

If your monthly payment does not reduce.

[Sidney Lupkin]

Your principal by at least $50, the.

[Lisa Hagan]

Federal government will essentially top you off to reduce that principal by $50.

[Cory Turner]

Think of it as like small scale loan forgiveness on a monthly basis and it will even lowest income borrowers actually see their balances go down, which is a big deal. One more change I need to mention here is the RAP plan will require even those lowest income borrowers to make at least a $10 monthly payment.

[Adrian Ma]

What about the bigger kind of loan forgiveness? Does this RAP plan offer anything like that?

[Cory Turner]

It does, but not for 30 years. Here's Preston Cooper at the conservative leaning American Enterprise Institute. He's been crunching the numbers on this.

[Lisa Hagan]

Borrowers who have typical levels of debt and typical incomes for their degree level are almost always going to pay off well before they hit that 30 year mark. So going into wrap, I wouldn't be thinking about forgiveness because you're probably going to pay it off before you hit 30 years.

[Cory Turner]

A few caveats, though, Adrian. Borrowers can still qualify for public service loan forgiveness. That program has not gone away. There is also one loan forgiveness option, but it's only available to current borrowers, not new borrowers.

[Adrian Ma]

What about people with loans right now? What do they need to know?

[Cory Turner]

Current borrowers, legacy borrowers will have several options from older plans that are not going away. Before I get to those, though, I want to call out one plan in particular, the Biden era save plan. 8 million people are enrolled in it. It was the subject of lawsuits. Those borrowers are currently in a really weird legal limbo where they're not required to make payments. But we know the Education Department just announced their LO will once again be accruing interest as of August 1st. So this law winds the SAVE plan down by 2028. So these borrowers are going to need to find an alternative repayment plan. Now, the extra options that are available to these legacy borrowers, one of them that might make a lot of sense to folks, including some of these save borrowers, is something called ibr. It stands for Income Based Repayment. It's just an older income plan compared to the new wrap plan, and it does still promise loan forgiveness after 20 or 25 years. So it might be a good option for folks on SAVE or even other legacy borrowers who are trying to figure out what plan makes sense for them.

[Adrian Ma]

One last question for you, Corey. President Trump has been talking a lot about trying to close the Education Department. So who would actually make all these huge changes to the loan programs?

[Cory Turner]

We know the Trump administration is exploring moving student loans either to the Small Business Administration or to Treasury. And at the same time, they're pushing really deep staffing cuts. The Education Department and specifically the Office of Federal Student Aid, or fsa, which oversees student loans, their staffing levels have been cut roughly in half. And so department staff are really in this kind of surreal, liminal space right now, where earlier this week the Supreme Court just gave President Trump the green light to keep gutting the Education Department at the same time that Congress has just passed passed this new law, essentially telling these same department workers, boy, do we have a job for you.

[Adrian Ma]

NPR's education correspondent, Cory Turner. Thanks for your reporting.

[Cory Turner]

Thanks for having me, Adrian.

[Adrian Ma]

And that's up first for July 19, 2025. I'm Adrian Ma.

[Scott Simon]

And I'm Scott Simon. Today's podcast was produced by the swift and talented Elena Turek, with help from Andy Craig, Gabriel Donatoff and and Fernando Naro. They're also swift as arrows and as sharp.

[Adrian Ma]

And our editors are Brett Neely, Scott Hensley, Steve Drummond, Dee Parvaz and Melissa Gray. She's the one with the pain relievers.

[Scott Simon]

On her desk, but the following people do not cause her any pain. David Greenberg, our technical director and our engineering support, Zoe Van Genhoven, Valentina Rodriguez Sanchez and Zach Coleman.

[Adrian Ma]

Pointing the finger today and really every day is Danny Hensel. He's our director and he's not alone. Fernando Naro is the wind beneath his wings.

[Scott Simon]

Our overlords are Shannon Rhodes, acting senior supervising editor. She might have been in a few plays in high school. Evie Stone, executive producer, has been to a number of plays. Just ask her anything about Ibsen and the man who knows exactly when he's being played, the often imitated, never duplicated Jim Cain, our deputy managing editor.

[Adrian Ma]

Tomorrow on THE Sunday Story, five years after the death of George Floyd shocked the country, Aisha Roscoe speaks with Ryan Ross and his teenage son Gavin about the talk, the painful but necessary conversation black parents have with their children to prepare them for encounters with police.

[Scott Simon]

And for more news, interviews and analysis, you can tune into WEEKEND EDITION on your radio. Go to stations.NPR.org to find your local NPR station.

[Judy Abrams]

This message comes from Warby Parker. What makes a great pair of glasses at Warby Parker? It's all the invisible extras without the extra cost, like free adjustments for life. Find your [e-mail] or visit one of their hundreds of stores around the country. This message comes from Mint Mobile. If you're tired of spending hundreds on big wireless bills, bogus fees and free perks, Mint Mobile might be right for you with plans starting from 15 bucks a month. Shop plans [e-mail] Switch upfront payment of $45 for 3 month 5GB plan required. New customer offer for first 3 months only, then full price plan options available, taxes and fees extra. See Mint Mobile for details. This message comes from NPR sponsor Thrive Market. Thrive Market's biggest sale of the summer is on, and it's the perfect time to stock up on healthy groceries. For a limited time, get an extra 25% off low sugar snack packs, organic dinner, staples and so much more, all delivered right to your door. Skip the store, dodge the markups and grab your healthy favorites. Go to thrivemarket. Com podcast for 30% off your first order and a free $60 gift.